The Hyper IgM Foundation Blog 

The Hyper IgM Foundation joins the primary immune deficiency treatment consortium (PIDTC)

Oct 23, 2019

The Hyper IgM Foundation is proud to announce that it joins the Primary Immune Deficiency Treatment Consortium (PIDTC) as one of its Patient Advocacy Group (PAG) partners. The PIDTC consists of 42 centers in North America whose shared goal is to improve the outcome of patients with rare, life-threatening, inherited disorders of the immune system. Basic scientists, immunologists, and transplant physicians from the participating centers have contributed much of the current knowledge of the cause and treatments of PID. The immediate focus of the consortium is to concentrate on three severe immune disorders which can be cured by hematopoietic stem cell transplantation, enzyme replacement, and/or or gene therapy by bringing together physicians/scientists who evaluate and care for the majority of children with PID in North America.

We are happy to share with our community the PIDTC’s October 2019 Newsletter that goes out to all their researchers. Page 4 was dedicated to welcoming the Hyper IgM Foundation as a PAG member of the consortium. Check out the whole newsletter and especially page 4.

Oct 2019 PIDTC Newsletter Issue 10